Heme Malignancy
SHOP PRODUCTSOverview
Molecular profiling of heme malignancies using NGS has transformed patient care, expanding the scope beyond traditional methods such as FISH and qPCR. NGS assays for profiling patients with blood cancers provide a highly multiplexed analysis of genomic aberrations underpinning many of these diseases. Assay development, validation and clinical deployment often require patient samples to aid these efforts. However, due to the vast diversity of genetic alterations in blood cancers, it can be difficult and expensive to source sufficient quantities of remnant patient specimens and cell lines bearing clinically relevant variants.
To accelerate and lower the cost of validating NGS assays for these disorders, SeraCare has developed highly multiplexed, bespoke biosynthetic DNA and RNA reference materials for NGS-based assays designed to analyze hematologic malignancies such as Myeloid Leukemia and Lymphoma.
Features & Benefits
- Expert-designed reference materials with clinically relevant variants for diagnostics, prognostics, and therapeutics of different blood cancers
- Highly multiplexed, covering broad variant types - SNVs, INDELs, and gene fusions
- Blended against a well-characterized GM24385 WT cell line background.
- Variant allele frequencies (VAFs) range from 0.1% to 15% based on digital PCR quantitation.
- Manufactured in GMP-compliant and ISO 13485-certified facilities.
Seraseq® Myeloid Solutions
| Product Name |
Product Number |
Format |
Genes Covered |
Number of Variants |
Target Allele Frequency
or Copy Number
|
| Seraseq Myeloid Fusion RNA Mix |
0710-0407 |
Purified RNA |
BCR-ABL1, ETV6-ABL1 (transcript 1), ETV6-ABL1 (transcript 2), FIP1L1-PDGFRA, MYST3-CREBBP, PCM1-JAK2, PML-RARA, RUNX1-RUNX1T1, TCF3-PBX1
|
9 |
>500copies/ul |
|
Seraseq Myeloid Mutation DNA Mix
|
0710-0408 |
Purified DNA |
ABL1, ASXL1, BRAF, CALR, CBL, CEBPA, CSF3R, FLT3, IDH1, JAK2, MPL, MYD88, NPM1, SF3B1, SRSF2, U2AF1
|
23 |
5%, 10%, or 15% |
|
Seraseq Myeloid ctDNA Mix WT
|
0710-2646 |
Purified ctDNA |
N/A |
N/A |
0% |
|
Seraseq Myeloid ctDNA Mix AF0.1%
|
0710-2647 |
Purified ctDNA |
N/A |
N/A |
0% |
|
Seraseq Myeloid ctDNA Mix AF0.5%
|
0710-2648 |
Purified ctDNA |
ABL1, ASXL1, BRAF, CALR, CBL, CEBPA, CSF3R, EZH2, FLT3, IDH1, IDH2, JAK2, MPL, MYD88, NPM1, SF3B1 SRSF2
|
25 |
0.5% |
|
Seraseq Myeloid ctDNA Mix AF1%
|
0710-2649 |
Purified ctDNA |
N/A |
N/A |
1.0% |
Myeloid DNA reference materials comprise multiple VAFs (5%-15%) in purified DNA, or 0.1%-1.0% in ctDNA formats, as well as a comprehensive panel of myeloid-specific fusions in purified RNA format. These materials represent the ideal solutions for limit of detection determination and for sensitivity and accuracy evaluation.
These products are compatible with a range of NGS Myeloid assays, including:
- AmpliSeq™ for Illumina Myeloid Panel
- Thermo Fisher Oncomine® Focus and Oncomine Myeloid Research Assay
- Archer® VariantPlex® and FusionPlex® Panels
- Illumina TruSight® Myeloid Sequencing Panel
Seraseq® Lymphoma DNA Solutions
Lymphoma reference materials include multiple (5%-15%) VAFs in purified DNA format for limit of detection, sensitivity and accuracy studies, as well as an FFPE reference material to challenge the detection of clinically relevant variants in degraded patient samples.
| Product Name |
Material Number |
Format |
Genes Covered |
Number of Variants |
Target Allele Freqeuency
|
| Seraseq FFPE Lymphoma DNA Reference Material |
0710-2202 |
FFPE |
BCL2, BIRC3-MALT1, BRAF, CCND1-CDC42BPB, CXCR4, EZH2, HSP90AA1-BCL6, IDH2, MYC-IGH, MYD88, NOTCH1, NOTCH2, NPM1-ALK, RHOA, SF3B1, STAT3, STAT5B, TBL1XR1-TP63, TP53 |
26 |
~5-10% |
| Seraseq Lymphoma DNA Mutation Mix |
0710-2203 |
Purified DNA |
